Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
UMass Metabolic NetworkGraduate School of Biomedical Sciences, MD/PhD Program
Graduate School of Biomedical Sciences, Immunology and Microbiology Program
Department of Dermatology
Document Type
Journal ArticlePublication Date
2017-08-01Keywords
Allergy and ImmunologyCellular and Molecular Physiology
Dermatology
Immune System Diseases
Skin and Connective Tissue Diseases
Metadata
Show full item recordAbstract
Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting the regeneration of melanocytes. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies, their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments.Source
J Allergy Clin Immunol. 2017 Sep;140(3):654-662. doi: 10.1016/j.jaci.2017.07.011. Epub 2017 Aug 1. Link to article on publisher's siteDOI
10.1016/j.jaci.2017.07.011Permanent Link to this Item
http://hdl.handle.net/20.500.14038/36597PubMed ID
28778794Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.jaci.2017.07.011